Goal Review Times Set in Latest Generic User-Fee Meetings

Washington Drug Letter
The FDA and generic-drug makers hope to reduce the backlog of ANDAs within five years and by that time have applications for generics reviewed within 10 months, according to the latest in negotiations for generic-drug user fees.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00